Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Marna G. Bouwhuis(Erasmus MC), Rajiv Kumar(Army Hospital Research and Referral), Alexander M.M. Eggermont(University Medical Center Utrecht), Adina Figl(German Cancer Research Center), Kari Hemminki(German Cancer Research Center), Andreas Gast(German Cancer Research Center), Dirk Schadendorf(National Center for Tumor Diseases)
Cited by 61
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k